Research Study

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study
Principal Investigator 
John Swiston

Overview

Body Locations and Systems 
ClinicalTrials.gov# 
NCT02558231
Status 
Recruiting
Study Start/End 
Feb 24, 2016 to Dec 31, 2018
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Dennis Solomon, Research Coordinator
Phone 
604-875-4111 ext.69831
Purpose of Study 

The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.